spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  atorvastatin 

 HSMN NewsFeed - 13 Jan 2022
PANTHERx Rare(R) Selected by Xeris Pharmaceuticals to Distribute Recorlev(R) (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients with Cushing's Syndrome
Biopharmaceuticals Distribution
 HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET(R) (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jul 2019
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Jan 2016
Merck Receives FDA Approval of ZEPATIER(TM) (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Sep 2015
AbbVie's VIEKIRAX(R) (ombitasvir/paritaprevir/ritonavir tablets) Receives Approval in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Nov 2013
Merck’s New Drug Application for an Investigational Intravenous (IV) Formulation of NOXAFIL(R) (posaconazole) Receives FDA Priority Review
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 22 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 20 May 2013
OrbusNeich's Genous(TM) Stent Associated With Lower Restenosis Rate Compared to Bare Metal Stents in Low-Risk Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 23 May 2011
FDA Approves INCIVEK(TM) (telaprevir) for People with Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Sep 2010
Celera Signs Agreement with Abbott for Distribution of CE-marked KIF6 Test to Identify Patients at Risk of Coronary Heart Disease
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 19 Jul 2010
Abbott's PROGRESS Study of Kaletra and Isentress Compared with a Standard HIV Regimen Meets the Pre-Specified Primary Efficacy Endpoint
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 28 Apr 2010
Abbott Receives FDA Approval for Once-Daily Dosing of Kaletra(R) (lopinavir / ritonavir) for Treatment-Experienced Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 2 Dec 2009
Watson Completes Acquisition of Arrow Group
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Sep 2009
Aileron Appoints Industry Veteran Diane Jorkasky, M.D., as Company's Head of Development and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2009
Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 29 Mar 2009
New Data for Abbott's TRILIPIX(R) (fenofibric acid) in Combination with Rosuvastatin Calcium Shows Improvement on Key Lipids for Cholesterol Management
Biopharmaceuticals
 HSMN NewsFeed - 15 Dec 2008
Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Sep 2008
Dr. Michael Beckert Steps Down as EVP and CMO of LifeCycle Pharma Effective December 31, 2008
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 29 Aug 2008
Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 25 Aug 2008
Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Aug 2008
Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Aug 2008
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Jun 2008
Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 31 May 2008
Phase III Study of Abbott's Investigational TriLipix(TM) in Combination With AstraZeneca's CRESTOR(R) Meets Primary Endpoints on Key Lipids
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2008
New Analysis Showed That High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 May 2008
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Devices Interventional
 HSMN NewsFeed - 1 May 2008
Esperion Therapeutics Completes $22.75 M Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Apr 2008
High-Dose Lipitor Reduced the Risk of Heart Attack and Stroke in Patients with Chronic Kidney Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Apr 2008
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 31 Mar 2008
Abbott's Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
First Statin Monotherapy to Achieve Regression of Coronary Atherosclerosis by Angiography in a Major Clinical Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Feb 2008
Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact
Biopharmaceuticals Generics Cardiology Litigation
 HSMN NewsFeed - 25 Jan 2008
Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 15 Jan 2008
First Head to Head Study Comparing Crestor(TM) and Lipitor(R) Effects on the Treatment of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Jan 2008
Patients Treated with Lipitor Were Significantly Less Likely to Have a Cardiovascular Event Than Those Treated with Simvastatin, New Observational Study Shows
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Jan 2008
Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Jan 2008
Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Nov 2007
Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra(R) (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
Biopharmaceuticals HIV/AIDS FDA
 HSMN NewsFeed - 6 Nov 2007
Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Oct 2007
Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Oct 2007
Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Sep 2007
Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Jul 2007
Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 12 Jul 2007
Resverlogix Corp.: Dr. Roger Newton, Co-Discoverer of Lipitor(R), Commences his Board of Directors Position
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jun 2007
Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 23 Jun 2007
New Study Demonstrates Colesevelam HCl Lowers Both A1C and LDL Cholesterol in Patients With Uncontrolled Type 2 Diabetes Mellitus on Metformin-Based Regimen
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 30 May 2007
Pfizer and Express Scripts Sign Agreement
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 May 2007
Ranbaxy Successfully Challenges Atorvastatin Patents in Norway
Biopharmaceuticals Litigation Generics
 HSMN NewsFeed - 29 May 2007
Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway
Biopharmaceuticals Litigation Generics
 HSMN NewsFeed - 17 May 2007
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2007
Daiichi Sankyo, Inc. Announces Filing For WelChol Label Change to Include Ezetimibe Efficacy Data
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Mar 2007
Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Mar 2007
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Mar 2007
Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Mar 2007
Lipitor Significantly Reduced the Risk of Serious Cardiovascular Events Compared With Simvastatin in an 80,000-Patient Analysis of a Real-World Managed Care Database
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Feb 2007
Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product
Biopharmaceuticals Litigation Generics
 HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2007
New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Coronary Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Jan 2007
Astellas and Pfizer Reached Settlement on Declaratory Judgment Action Relating to Lipitor Agreement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 25 Jan 2007
Pfizer Gains Favorable Ruling From Canadian Court on Lipitor Basic Patent, Will Appeal Ruling on Calcium Salt Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 2 Jan 2007
Daiichi Sankyo, Inc. Announces Filing of Supplemental New Drug Application for WelChol in the Treatment of Type 2 Diabetes Mellitus
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Dec 2006
Data Recently Published in Mayo Clinic Proceedings Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor (atorvastatin) in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Dose Comparisons Studied
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2006
Australian Federal Court Grants Favorable Decision to Ranbaxy on Pfizer's Atorvastatin Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Dec 2006
Risk of Heart Attack Significantly Reduced in About 90 days by Modern Combination of Drugs
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Dec 2006
In Interests of Patient Safety, Pfizer Stops All Torcetrapib Clinical Trials; Company Has Notified FDA and is in the Process of Notifying All Clinical Investigators and Other Regulatory Authorities
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 15 Nov 2006
Intensive Lipitor Therapy Reduced Heart Attack and Stroke By One-Third In Patients With Chronic Kidney Disease, New Analysis Shows
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 Nov 2006
New Study Confirms WelChol Improves Glycemic Control in Patients With Uncontrolled Type 2 Diabetes Mellitus on Insulin
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
Biopharmacetuicals Cardiology
 HSMN NewsFeed - 13 Nov 2006
Interim Analysis of New Study Suggests Boosted INVIRASE(R) May Achieve Similar Levels of HIV Suppression to Boosted Lopinavir with a Favorable Lipid Profile
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 13 Nov 2006
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2006
Pfizer Updates Preliminary Results of Torcetrapib/Atorvastatin Clinical Trials as Abstract for Phase 3 Study is Released
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 27 Oct 2006
European Patent Office Supports Validity of Lipitor Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 23 Oct 2006
U.S. Appeals Court Denies Ranbaxy Petition for Rehearing Regarding Main Patent in Lipitor Case
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 17 Oct 2006
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 5 Oct 2006
FDA Approves New Label for VYTORIN(R) (ezetimibe/simvastatin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Sep 2006
Ranbaxy Invalidates Pfizer's 281 Patent in The Netherlands
Biopharmaceuticals Litigation Generics
 HSMN NewsFeed - 6 Sep 2006
Lipitor More Effective Than Simvastatin in Cutting Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack, New Data Suggests
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Sep 2006
New EXPLORER Results Show Patients Achieved Dramatic Reductions in C-Reactive Protein And LDL-C Levels With CRESTOR Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Sep 2006
New Lipitor Data Published in The Lancet
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 29 Aug 2006
Ranbaxy Wins on Two Additional Atorvastatin Patents in Norway
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 Aug 2006
Pfizer's Lipitor Shown to Reduce the Chance of Additional Strokes in Stroke Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Aug 2006
Ranbaxy Invalidates Pfizer's '995 Lipitor U.S. Patent
Biopharmaceuticals Cardiology Generics Litigation
 HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2006
New Data Shows CRESTOR(R) Helped African American, Hispanic American and South Asian American Patients Significantly Lower LDL-C and Achieve Cholesterol Goals
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 19 Jun 2006
New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL 'Bad' Cholesterol at All Doses Compared
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2006
Aegerion Pharmaceuticals Completes $22.5 Million Series A Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Jun 2006
New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor in Reducing LDL ''Bad'' Cholesterol in Patients with Type II Diabetes at the Recommended Usual Starting Doses
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jun 2006
Pfizer Statement on Lipitor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
Pfizer's Lipitor Provides Greater Reductions in Heart Attack, Stroke and Cardiovascular Procedures at an Overall Cost Savings Compared to Zocor, New Analysis Shows
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 15 May 2006
CRESTOR Helped More Patients Reach Goal in MERCURY II Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 25 Apr 2006
Pfizer Says Austrian Court Ruling on Lipitor Enantiomer Patent Has No Effect on Cases in Other Jurisdictions
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 18 Apr 2006
First Data to Show Addition of a Bile Acid Sequestrant (WelChol, colesevelam HCl) to Statin Therapy Significantly Reduces Median hs-CRP Levels
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Apr 2006
Inflammatory-Enzyme Shown to Predict Risk of Cardiovascular Events After Acute Coronary Syndromes
Biopharmaceuticals Diagnostics Cardiology
 HSMN NewsFeed - 24 Mar 2006
First-Ever Large-Scale Prospective Study in Hispanic Patients With Elevated Cholesterol Demonstrates Significant Cholesterol Reductions With CRESTOR(R)
Biopharmaceuticals
 HSMN NewsFeed - 14 Mar 2006
New Torcetrapib/Atorvastatin Research Further Supports Raising 'Good' HDL Cholesterol
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Mar 2006
New Analysis Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor(R) in Achieving Lower Levels of LDL (''bad'') Cholesterol, Apolipoprotein B and C-Reactive Protein
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Feb 2006
Roche to Focus Resources on Availability of INVIRASE(R), Now Preferred Formulation of Saquinavir
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 19 Jan 2006
Open-Label Study Shows No Significant Effects on the Pharmacokinetics of a Single Dose of TRIGLIDE(TM) (Fenofibrate) Tablets When Combined With Lipitor(R) (Atorvastatin) or Zocor(R) (Simvastatin)
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 55

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 55 additional stories matching:
atorvastatin
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.